AXIOS October 2, 2022
Competition is intensifying in the DNA sequencing industry, which has long been dominated by sequencing behemoth Illumina.
Driving the news: Illumina, which has an estimated 80% share of the global gene sequencing market, unveiled a new line of instruments today that it says will cut the cost of genome sequencing — the latest in a flurry of announcements from an industry in pursuit of faster and cheaper offerings.
What they’re saying: “It’s Illumina’s response to the competition,” says Jay Shendure, a professor of genome sciences at the University of Washington.
- Element Biosciences, a startup with a benchtop sequencer already on the market, announced updated specifications this week that CEO Molly He says will support its market play to offer...